Ulcer‐free days following treatment for diabetic foot ulcers (free from any recurrence) · people with diabetes and foot ulcers
1 finding from 1 review
Complete closure · people with diabetes and foot ulcers
Any growth factor may leads to higher complete wound closure compared with placebo or no growth factor (low certainty).
1 finding from 1 review
Lower limb amputation (minimum of one toe) · people with diabetes and foot ulcers
It is very uncertain whether any growth factor changes lower limb amputation (minimum of one toe) compared with placebo or no growth factor (very low certainty).
1 finding from 1 review
Time to ulcer closure ‐ not reported · people with diabetes and foot ulcers
1 finding from 1 review
Quality of life · people with diabetes and foot ulcers
1 finding from 1 review
Adverse events (non‐serious and serious) · people with diabetes and foot ulcers
Any growth factor showed no clear difference in adverse events (non‐serious and serious) compared with placebo or no growth factor (low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
1 finding from 1 review
Any limb amputation ( · Individuals with peripheral arterial disease
Growth factors may leads to lower any limb amputation ( compared with placebo or no therapy (low certainty).
1 finding from 1 review
Any adverse event ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in any adverse event ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
Transforming growth factor-beta(2) (TGF-beta2) showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported
Show 1 more finding
Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review
Oral mucositis (any severity) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (any severity) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-colony stimulating factor (G-CSF) led to lower oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.
2 findings from 1 review
Adverse outcomes at any time point · people with BRVO
Anti‐VEGF probably leads to lower adverse outcomes at any time point compared with steroid (moderate certainty).
1 finding from 1 review
Adverse outcomes at any time point · macular oedema secondary to branch retinal vein occlusion
It is very uncertain whether anti‐VEGF changes adverse outcomes at any time point compared with sham (very low certainty).
1 finding from 1 review
Adverse outcomes at any time point · people with BRVO
It is very uncertain whether anti‐VEGF changes adverse outcomes at any time point compared with laser (very low certainty).
1 finding from 1 review